Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tyrosine-protein phosphatase non-receptor type 1 (PTP1B) is an intracellular enzyme that belongs to the protein tyrosine phosphatase (PTP) family. It acts primarily as a negative regulator of several signaling pathways, most notably the insulin signaling pathway. It dephosphorylates tyrosine residues on target proteins, including insulin receptor kinase (IRK), EGF receptor, and PDGF receptor, modulating key cellular processes including metabolism, cell growth/proliferation, differentiation, and response to stress. It is considered a promising therapeutic target for type 2 diabetes and is also implicated in cancer biology.
Inhibition of PTP1B activity, leading to increased tyrosine phosphorylation of target proteins (e.g., insulin receptor)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tyrosine-protein phosphatase non-receptor type 1 (PTP1B).